Cart
sales@molnova.com
OS-3-106
CAS No. 1580000-17-4
OS-3-106( —— )
Catalog No. M23687 CAS No. 1580000-17-4
OS-3-106 is a novel arylamide phenylpiperazines, as partial agonists at the D3R in the adenylyl cyclase inhibition assay.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 61 | In Stock |
|
| 50MG | 104 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOS-3-106
-
NoteResearch use only, not for human use.
-
Brief DescriptionOS-3-106 is a novel arylamide phenylpiperazines, as partial agonists at the D3R in the adenylyl cyclase inhibition assay.
-
DescriptionOS-3-106 is a novel arylamide phenylpiperazines, as partial agonists at the D3R in the adenylyl cyclase inhibition assay.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorD3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1580000-17-4
-
Formula Weight450.6
-
Molecular FormulaC25H30N4O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCOC1=CC=CC=C1N2CCN(CC2)CCCCNC(=O)C3=CC=C(C=C3)C4=CSC=N4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Cheung T , Loriaux A L , Weber S M , et al. Reduction of cocaine self-administration and D3 receptor-mediated behavior by two novel dopamine D3 receptor-selective partial agonists, OS-3-106 and WW-III-55.[J]. Journal of Pharmacology & Experimental Therapeutics, 2015, 347(2):410-23.
molnova catalog
related products
-
Amantadine hydrochlo...
Amantadine Hydrochloride is an antiviral and an antiparkinsonian drug.
-
Spiperone
A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
-
Ecopipam
Ecopipam (UNII-0X748O646K) is a potent, selective, and orally active antagonist of dopamine D1/D5 receptors, with Kis of 1.2 nM and 2.0 nM, respectively.
